Todd R. Golub

TL;DR: It is established that germline nonsense and frameshift variants in PALB2, but not in ATM or CHEK2, can also give rise to the same signature and epigenetic silencing of RAD51C and BRCA1 by promoter methylation is strongly associated with signature 3.

TL;DR: An unsupervised subclass mapping method (SubMap), which reveals common subtypes between independent data sets and identifies common sub types of breast cancer associated with estrogen receptor status and a subgroup of lymphoma patients who share similar survival patterns, thus improving the accuracy of a clinical outcome predictor.

TL;DR: These studies identify unique combinations of genetic alterations in discrete LBCL subtypes and subtype-selective bases for targeted therapy and characterize their recurrent somatic mutations, chromosomal rearrangements, copy number alterations (CNAs), and associated driver genes.

TL;DR: The results reveal the immense potential for translating the dispersed expertise in biological assays involving human pathogens into drug discovery starting points, by providing open access to new families of molecules, and emphasize how a small additional investment made to help acquire and distribute compounds, and sharing the data, can catalyze drug discovery for dozens of different indications.

TL;DR: Clinical applications of DNA microarrays, some important recent studies, promising avenues of research in this emerging field of study, and the likely impact that expression profiling will have on clinical oncology are discussed.